| Literature DB >> 35028714 |
Hiroshi Kitoh1,2, Masaki Matsushita3, Kenichi Mishima3, Yasunari Kamiya3, Kenta Sawamura3.
Abstract
Achondroplasia (ACH) is the most common skeletal dysplasia and characterized by a disproportionate short stature, macrocephaly with frontal bossing, exaggerated lumbar lordosis, and trident hands. It is induced by activated mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. In addition to short stature, patients with ACH have a high prevalence of medical complications, including upper airway obstructive apnea, increased mortality, foramen magnum stenosis, hydrocephalus, developmental delay, recurrent ear infections, genu varum, obesity, and spinal canal stenosis, throughout their whole life. Several investigational drugs that modulate abnormal FGFR3 signaling have recently emerged, vosoritide being the most developed. This review presents the different disease-specific complications of ACH occurring in neonates, infants, childhood, adolescent, and adults and reports the current multidisciplinary interventions for these various complications. Moreover, we propose treatment strategies for children with ACH from the perspective of quality of life in adulthood.Entities:
Keywords: Achondroplasia; Complications; Current management; Quality of life; Therapeutic strategy
Mesh:
Year: 2022 PMID: 35028714 DOI: 10.1007/s00774-021-01298-z
Source DB: PubMed Journal: J Bone Miner Metab ISSN: 0914-8779 Impact factor: 2.626